Acne Vulgaris — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for acne vulgaris. 228 active patents protecting 11 drugs from 8+ originators. First major cliff: 2033. Daily refresh.

11
Approved drugs
228
Active US patents
65/100
Avg vulnerability
—
Annual revenue covered

Originators in Acne Vulgaris

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer 104 patents Exeltis Usa Inc 42 patents Mayne Pharma 38 patents Generic (originally Pfizer) 15 patents Galderma Labs Lp 14 patents Sun Pharma 8 patents Leo Pharma As 4 patents Bausch Health 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating acne vulgaris. Each bar = one year. Y-axis scaled to peak year (82 patents).

3
26
8
27
24
28
18
29
13
30
31
31
82
32
7
33
6
34
6
36
2
37
5
38
14
40
4
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Estrace
ESTRADIOL
 Pfizer 101 37 — 2028-07-10
Slynd
DROSPIRENONE
 Exeltis Usa Inc 42 64 — 2028-01-15
Benzamycin
BENZOYL PEROXIDE
 Mayne Pharma 38 70 — 2028-02-03
Differin
ADAPALENE
 Galderma Labs Lp 14 75 — 2026-09-15
Cortef
hydrocortisone
 Generic (originally Merck/Upjohn) 14 64 — 2032-11-19
Winlevi
CLASCOTERONE
 Sun Pharma 8 72 — 2027-01-12
Azelex
AZELAIC ACID
 Leo Pharma As 4 65 — 2027-09-18
Cleocin T
CLINDAMYCIN PHOSPHATE
 Pfizer 3 68 — 2026-12-02
Retin-A
TRETINOIN
 Bausch Health 2 66 — 2038-08-22
Vibramycin
doxycycline
 Generic (originally Pfizer) 1 80 — 2027-12-19
Aczone
DAPSONE
 Almirall 1 50 — 2033-11-18

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12337002 Winlevi method of use 88 2028-07-24
8435502 Differin method of use 85 2026-09-15
8709392 Differin method of use 85 2026-09-15
9868103 Benzamycin method of use 83 2028-08-08
11207332 Winlevi method of use 83 2028-11-20
12070629 Benzamycin method of use 81 2030-12-30
11951213 Slynd method of use 81 2031-06-28
11951213 Slynd method of use 81 2031-06-28
12090231 Slynd method of use 81 2031-06-28
12090231 Slynd method of use 81 2031-06-28

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11795178 Estrace composition of matter 0 2033-09-27
12325714 Estrace composition of matter 0 2033-09-27
11865179 Estrace composition of matter 0 2032-11-21
11865179 Estrace composition of matter 0 2032-11-21
8231906 Estrace composition of matter 0 2030-07-04
8231906 Estrace composition of matter 0 2030-07-04
8231906 Estrace composition of matter 0 2030-07-04
8231906 Estrace composition of matter 0 2030-07-04
8231906 Estrace composition of matter 0 2030-07-04
7300935 Estrace composition of matter 0 2029-01-28

Related